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Test ing t imes! Choosing Wisely when it comes
to monitoring type 2 diabetes
Harnessing the value of self -monitoring of blood glucose among people w ith
non- insulin- t reated type 2 diabetes
A ffecting over one million Australians, type 2diabetes (T2D) costs our country an unsustainable$15 billion annually,1 and is predicted to be the
nation’s leading cause of disease burden by 2017.2 It is
therefore essential to engage people with this condition in
cost-effective therapy to reduce these costs, which arise
mostly from treating the long-term complications (eg,
blindness, stroke, amputation).
Self-monitoring of blood glucose levels (by means of a
finger-prick blood sample analysed with an ambulatory
blood glucose meter) is an essential part of managing
type 1 diabetes and insulin-treated T2D; however, the
clinical benefit for people with T2D who are not using
insulin is, and we believe remains, a matter of debate.
The Government decides ...
On 29 May 2015, the Australian federal government
announced that access to testing strips for self-monitoring
of blood glucose (SMBG) would be limited for most
people with T2D. This announcement followed a much
anticipated 2-year review process and extensive
consultation. The Pharmaceutical Benefits Scheme (PBS)
now stipulates that:
 unrestricted access to SMBG strips will continue
for people with T2D who are using insulin or other
medicines (eg, corticosteroids, sulfonylureas) to
detect asymptomatic hypoglycaemia, or during
illness that may cause fluctuations in blood glucose
level;3 and
 access will now be restricted for those with
T2D “who are not using insulin and who have
their blood glucose level under control. The PBAC
[Pharmaceutical Benefits Advisory Committee]
recommended that these patients be limited to a
six month supply [100 strips] following changes to
their diabetes management, with a further six
months’ supply available at the prescriber’s
discretion.” 3
This second stipulation is more specific but consistent
with another recommendation released just a month
earlier.
Choosing Wisely Aust ral ia recommends ...
Among its 25 recommendations published on 29 April
2015, Choosing Wisely Australia (an initiative of
NPS MedicineWise), in collaboration with the Royal
Australian College of General Practitioners, made
only one about diabetes. This was: “Don ’t advocate
routine self-monitoring of blood glucose for people with
type 2 diabetes who are on oral medication only.” 4
Originating in the United States, Choosing Wisely is
a laudable global movement encouraging clinicians
and consumers to question the use of unnecessary
medical tests, treatments and procedures.
In the US and Canada, Choosing Wisely
recommendations for diabetes have focused similarly on
restricting SMBG strips for people with non-insulin-
treated T2D; in the United Kingdom, recommendations
are expected in late 2015.
Despite nuances of language in these international
recommendations, SMBG among people with non-
insulin-treated T2D is clearly a “ hot topic” .
The evidence base indicates ...
In 2012, two highly influential systematic reviews— a
Cochrane review and a meta-analysis— were
published.5,6 Based largely on the same set of randomised
controlled trials (RCTs), their conclusions were
comparable: “ clinical benefit is limited ” for SMBG in
people with non-insulin-treated T2D.
The Cochrane review5 included 12 RCTs (3249
participants). Among these, nine trials of 6 months’
duration found that glycated haemoglobin (HbA1c) levels
were reduced on average by 0.3% (a statistically, but not
clinically, significant improvement).5 There was no
significant reduction in HbA1c levels in trials with 12
months of follow-up. Overall, no benefit was shown for
patient satisfaction, emotionalwellbeing or health-related
quality of life, and SMBG was considered unlikely
to be cost-effective.5
Challenging t he evidence and assumpt ions
Our own critical appraisal revealed too much variation in
trial methods and populations to draw firm conclusions
about the value of SMBG overall.7 In particular, in some
trials, participants were not given instructions about
when or how often to check their blood glucose level
(or this was not reported). Among trials where frequency
was reported, it varied enormously — from four times
per month to six times per day, 7 days per week. In most
cases, the SMBG conducted was insufficient to provide
interpretable blood glucose patterns that could inform
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diabetes self-management and lifestyle choices (eg, food
intake or physical activity). Some studies incorporated
feedback and education about self-management, but
others did not.
We refer to this random, low frequency, routine SMBG as
“ unstructured ” , and suggest it is ineffective because it
does not enable people with T2D or health professionals
to detect blood glucose level patterns or act upon them.
Indeed, people with non-insulin-treated T2D reported
that their GPs rarely refer to their glucose diary data, and
perceive this to mean that SMBG is worthless.7 They
experience SMBG as “ frustrating” , “ painful” ,
“ inconvenient” and “ expensive” , they lack motivation for
it, and report “ feelings of failure or anxiety in response
to high blood glucose readings” .7
However, in studies where the protocol for a
“ structured” approach to SMBG was clearer, the
findings were more positive— reduced HbA1c levels,
less glycaemic variability overall, less time spent in
hyperglycaemia.5,7
St ruct ured monit oring is ef fect ive,
econom ical and engaging
After the systematic reviews were concluded, an RCT of
structured SMBG was published.8 In the STeP study,
structured SMBG was defined as seven checks per day
over 3 consecutive days in the week before their
consultation with a doctor about their diabetes.8 STeP
showed that structured SMBG was associated with a
statistically significant reduction in HbA1c level ( 0.3%;
P < 0.001; intention-to-treat analysis), and a per protocol
analysis (focused on those who conducted structured
SMBG as intended) showed a clinically significant
reduction in HbA1c level ( 0.5%).8
Notably, trials of structured SMBG have also shown
important psychological benefits— increased satisfaction
with treatment, reduced diabetes-related distress,
improved general emotional wellbeing and greater
confidence in, and motivation for, diabetes self-care.7-9
The findings of the STeP study suggest that SMBG
does not have, as such, a dose-related response, and
needs to be viewed , rather, in terms of quality rather
than quantity of monitoring.8 The protocol suggests
that a person with non-insulin-treated T2D using
structured SMBG could use as few as 84 test strips per
year (ie, 21 in the week before each quarterly general
practitioner visit). This, in fact, compares very
favourably with the current Australian average of 300
strips per annum per person with non-insulin-treated
T2D, and suggests great potential for the federal
government’s restricted access policy (100 strips over
6 months) to be applied sensibly.
Our recent observational study, STeP-IT-UP, (involving
98 people with non-insulin-treated T2D attending 22
general practices across our eastern seaboard), showed
that structured SMBG is feasible in Australia.10
Furthermore, our findings support US and European
evidence showing significant reductions in HbA1c
levels (without increasing hypoglycaemia) and
diabetes-related distress.
What is st ruct ured SMBG?
Structured SMBG is more than just 21 finger pricks. It
involves meaningful (rather than random) glucose checks
at set times (eg, pre-meal and 2 hours post-meal, and
before bedtime) to generate a pattern over at least 3
consecutive days. The person with T2D also notes their
meal sizes and energy levels to provide context for the
readings. While most trials have evaluated SMBG as
though it were an active agent, it is actually just one aspect
of a complex intervention, requiring:
 agreement between the person with T2D and their
health professional on glucose targets and the
timing and frequency of SMBG;
 a supportive and enthusiastic health professional
trained in the interpretation of SMBG data;
 appropriate feedback to, and education for, the
person with T2D;
 collaborative review of the SMBG pattern to
determine areas for improvement and to discuss
what contributed to low, high or within-target
glucose levels;
 a plan for how to change diet, activity levels
or medication to improve glucose levels;
 action (ie, actual change in diet, activity levels
or medication); and
 motivation on the part of the person with T2D,
which is likely to be contingent on much of the
above being in place.
A closer look at t he Choosing Wisely
Aust ral ia recommendat ion
We take issue with Choosing Wisely’s initial statement,
that there “ is no evidence that self-monitoring of blood
glucose (SMBG) affects patient satisfaction, general
well-being or general health-related quality of life.” 4
There is compelling evidence on both sides of this
debate, depending on whether SMBG is structured
or unstructured .7
Choosing Wisely claimed that Australian Government
spending on glucose monitoring strips was $143 million
in 2012.4 This is true, but misleading. Only 35% of this
spending was for people with non-insulin-treated T2D.3
Most of this funding was for SMBG essential for
informing insulin dosing and detecting hypoglycaemia in
people with type 1 diabetes and those with T2D using
insulin or sulphonylureas. Substantial cost savings
therefore seem unlikely.
The most positive aspects of the Choosing Wisely
recommendation are the exceptions, in particular the
usefulness of SMBG for “ short-term education about
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diet influencing blood sugar” , although we would
expand this to include physical activity.
Choosing more Wisely Aust ral ia
We appreciate absolutely the need for evidence-based
medicine— and have described the complexity of this
evidence base. Nevertheless, we remain concerned that
restricting access to glucose monitoring strips conveys the
wrong message philosophically. At face value, it implies
that some forms of diabetes require less monitoring and
are, therefore, less serious than others. Yet all diabetes is
serious and all diabetes leads to complications if not
monitored and managed appropriately: conveying any
other message is confusing, inaccurate and potentially
dangerous.
As with most behaviour, if individuals do not value it, or
perceive more costs than benefits, they are unlikely to
instigate or maintain the behaviour. This applies not only
to people with non-insulin-treated T2D, but also to health
professionals. While the government is undoubtedly
interested in potential costs savings, the PBS final report
also recognises the need to emphasise to clinicians and
people with T2D that “ changes are being implemented to
encourage better practice and direct more attention to
appropriate use of test strips” .3
Far from recommending against routine SMBG, which
may unintentionally deter any SMBG in people with
non-insulin-treated T2D, we believe Choosing Wisely
Australia should positively advocate structured SMBG
for all people with T2D not using insulin or other
hypoglycaemia-inducing medications. This would be
more consistent with its mission not only to reduce
unnecessary medical tests, but also to promote
evidence-based clinical practice. Structured SMBG
offers an evidence-based model for effective blood
glucose monitoring and engagement in diabetes
self-management.
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